European News

• Newly established affiliate in Greece demonstrates Daiichi Sankyo’s ongoing commitment to serve as many people living with cancer as possible • In Greece, breast cancer is the leading cause of cancer-related death among women and lung cancer among men • Greece’s geographical location offers a…

Das forschende Pharma-Unternehmen Daiichi Sankyo aus Japan mit Europazentrale in München expandiert. In Zukunft sollen am Standort Pfaffenhofen neben Herzkreislauf-Medikamenten auch Therapien zur Behandlung von u.a. Brust-, Lungen- und Magenkrebs entwickelt und hergestellt werden. Der Ausbau des…

Supply Chain Due Diligence Act (Supply Chain Act): A Milestone for Human Rights and Corporate Responsibility At the beginning of the year, Daiichi Sankyo Europe GmbH (DSE) has published the principles and procedures of the Supply Chain Act in a policy statement on the DSE website. The Supply Chain…

Masahiro Kato takes over as Managing Director, Oliver Appelhans appointed to Head of the European Specialty Business Unit • Masahiro Kato appointed as Managing Director of Daiichi Sankyo Europe GmbH from 1st November 2023 • Masahiro succeeds Dr. Jan Van Ruymbeke who will retire on 31st of March…

On May 4th, 2023, Esperion Therapeutics Inc. issued a press release regarding their amended complaint against Daiichi Sankyo Europe GmbH. Daiichi Sankyo Europe GmbH (“DSE”) disagrees with the claim by Esperion Therapeutics Inc. in that press release, its original complaint, and its amended…

Tokyo, Munich and Basking Ridge, NJ – February 22, 2021 – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced Ken Takeshita, MD will be named the new Global Head of Research & Development as of April 1, 2021.  On that date, Dr. Junichi Koga will retire from the position,…

Ken Keller Appointed as Head of the Oncology Business Unit Overseeing Global Oncology Strategy and U.S. and European Oncology Businesses

• Agreement represents second collaboration between Daiichi Sankyo and AstraZeneca for a Daiichi Sankyo DXd antibody drug conjugate (ADC) • AstraZeneca to pay Daiichi Sankyo up to $6 billion in total consideration, including a $1 billion upfront payment and up to an additional $5 billion contingent…

Tokyo, Japan, Munich, Germany, Basking Ridge, NJ (November 4 / 5, 2019):  Daiichi Sankyo Co., Ltd announced today that the company has filed a Declaratory Judgement action in the District Court of Delaware in response to receiving communications from Seattle Genetics, Inc. with respect to a…

• Collaboration combines Daiichi Sankyo’s scientific and technological excellence with AstraZeneca’s global experience and resources in oncology to accelerate and expand the potential of [fam-] trastuzumab deruxtecan as monotherapy and combination therapy across a spectrum of HER2 expressing cancers…